1
|
Novel treatment strategies for acetylcholine receptor antibody-positive myasthenia gravis and related disorders. Autoimmun Rev 2022; 21:103104. [PMID: 35452851 DOI: 10.1016/j.autrev.2022.103104] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2022] [Accepted: 04/18/2022] [Indexed: 11/21/2022]
Abstract
The presence of autoantibodies directed against the muscle nicotinic acetylcholine receptor (AChR) is the most common cause of myasthenia gravis (MG). These antibodies damage the postsynaptic membrane of the neuromuscular junction and cause muscle weakness by depleting AChRs and thus impairing synaptic transmission. As one of the best-characterized antibody-mediated autoimmune diseases, AChR-MG has often served as a reference model for other autoimmune disorders. Classical pharmacological treatments, including broad-spectrum immunosuppressive drugs, are effective in many patients. However, complete remission cannot be achieved in all patients, and 10% of patients do not respond to currently used therapies. This may be attributed to production of autoantibodies by long-lived plasma cells which are resistant to conventional immunosuppressive drugs. Hence, novel therapies specifically targeting plasma cells might be a suitable therapeutic approach for selected patients. Additionally, in order to reduce side effects of broad-spectrum immunosuppression, targeted immunotherapies and symptomatic treatments will be required. This review presents established therapies as well as novel therapeutic approaches for MG and related conditions, with a focus on AChR-MG.
Collapse
|
2
|
Guidelines for pre-clinical assessment of the acetylcholine receptor--specific passive transfer myasthenia gravis model-Recommendations for methods and experimental designs. Exp Neurol 2015; 270:3-10. [PMID: 25743217 DOI: 10.1016/j.expneurol.2015.02.025] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2014] [Revised: 02/13/2015] [Accepted: 02/17/2015] [Indexed: 11/21/2022]
Abstract
Antibodies against the muscle acetylcholine receptor (AChR) are the most common cause of myasthenia gravis (MG). Passive transfer of AChR antibodies from MG patients into animals reproduces key features of human disease, including antigenic modulation of the AChR, complement-mediated damage of the neuromuscular junction, and muscle weakness. Similarly, AChR antibodies generated by active immunization in experimental autoimmune MG models can subsequently be passively transferred to other animals and induce weakness. The passive transfer model is useful to test therapeutic strategies aimed at the effector mechanism of the autoantibodies. Here we summarize published and unpublished experience using the AChR passive transfer MG model in mice, rats and rhesus monkeys, and give recommendations for the design of preclinical studies in order to facilitate translation of positive and negative results to improve MG therapies.
Collapse
|
3
|
Sommer N, Tackenberg B, Hohlfeld R. The immunopathogenesis of myasthenia gravis. HANDBOOK OF CLINICAL NEUROLOGY 2008; 91:169-212. [PMID: 18631843 DOI: 10.1016/s0072-9752(07)01505-9] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Affiliation(s)
- Norbert Sommer
- Clinical Neuroimmunology Group, Philipps-University, Marburg, Germany
| | | | | |
Collapse
|
4
|
Martínez-Martínez P, Losen M, Duimel H, Frederik P, Spaans F, Molenaar P, Vincent A, De Baets MH. Overexpression of rapsyn in rat muscle increases acetylcholine receptor levels in chronic experimental autoimmune myasthenia gravis. THE AMERICAN JOURNAL OF PATHOLOGY 2007; 170:644-57. [PMID: 17255332 PMCID: PMC1851878 DOI: 10.2353/ajpath.2007.060676] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The primary autoantigen in myasthenia gravis, the acetylcholine receptor (AChR), is clustered and anchored in the postsynaptic membrane of the neuromuscular junction by rapsyn. Previously, we found that overexpression of rapsyn by cDNA transfection protects AChRs in rat muscles from antibody-mediated loss in passive transfer experimental autoimmune myasthenia gravis (EAMG). Here, we determined whether rapsyn overexpression can reduce or even reverse AChR loss in muscles that are already damaged by chronic EAMG, which mimics the human disease. Active immunization against purified AChR was performed in female Lewis rats. Rapsyn overexpression resulted in an increase in total muscle membrane AChR levels, with some AChR at neuromuscular junctions but much of it in extrasynaptic membrane regions. At the ultrastructural level, most endplates in rapsyn-treated chronic EAMG muscles showed increased damage to the postsynaptic membrane. Although rapsyn overexpression stabilized AChRs in intact or mildly damaged endplates, the rapsyn-induced increase of membrane AChR enhanced autoantibody binding and membrane damage in severe ongoing disease. Thus, these results show the complexity of synaptic stabilization of AChR during the autoantibody attack. They also indicate that the expression of receptor-associated proteins may determine the severity of autoimmune diseases caused by anti-receptor antibodies.
Collapse
MESH Headings
- Animals
- Autoantibodies/immunology
- Autoantibodies/metabolism
- Chronic Disease
- Female
- Gene Expression
- Humans
- Motor Endplate/genetics
- Motor Endplate/immunology
- Motor Endplate/metabolism
- Motor Endplate/ultrastructure
- Muscle Proteins/biosynthesis
- Muscle Proteins/genetics
- Muscle Proteins/immunology
- Myasthenia Gravis, Autoimmune, Experimental/genetics
- Myasthenia Gravis, Autoimmune, Experimental/immunology
- Myasthenia Gravis, Autoimmune, Experimental/metabolism
- Myasthenia Gravis, Autoimmune, Experimental/pathology
- Rats
- Rats, Inbred Lew
- Receptors, Cholinergic/immunology
- Receptors, Cholinergic/metabolism
- Synaptic Membranes/immunology
- Synaptic Membranes/metabolism
Collapse
Affiliation(s)
- Pilar Martínez-Martínez
- Department of Neurology, Research Institute Brain and Behaviour, University of Maastricht, Maastricht University Hospital, The Netherlands.
| | | | | | | | | | | | | | | |
Collapse
|
5
|
Losen M, Stassen MHW, Martínez-Martínez P, Machiels BM, Duimel H, Frederik P, Veldman H, Wokke JHJ, Spaans F, Vincent A, De Baets MH. Increased expression of rapsyn in muscles prevents acetylcholine receptor loss in experimental autoimmune myasthenia gravis. ACTA ACUST UNITED AC 2005; 128:2327-37. [PMID: 16150851 DOI: 10.1093/brain/awh612] [Citation(s) in RCA: 59] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
Myasthenia gravis is usually caused by autoantibodies to the acetylcholine receptor (AChR). The AChR is clustered and anchored in the postsynaptic membrane of the neuromuscular junction (NMJ) by a cytoplasmic protein called rapsyn. We previously showed that resistance to experimental autoimmune myasthenia gravis (EAMG) in aged rats correlates with increased rapsyn concentration at the NMJ. It is possible, therefore, that endogenous rapsyn expression may be an important determinant of AChR loss and neuromuscular transmission failure in the human disease, and that upregulation of rapsyn expression could be used therapeutically. To examine first a potential therapeutic application of rapsyn upregulation, we induced acute EAMG in young rats by passive transfer of AChR antibody, mAb 35, and used in vivo electroporation to over-express rapsyn unilaterally in one tibialis anterior. We looked at the compound muscle action potentials (CMAPs) in the tibialis anterior, at rapsyn and AChR expression by quantitative radioimmunoassay and immunofluorescence, and at the morphology of the NMJs, comparing the electroporated and untreated muscles, as well as the control and EAMG rats. In control rats, transfected muscle fibres had extrasynaptic rapsyn aggregates, as well as slightly increased rapsyn and AChR concentrations at the NMJ. In EAMG rats, despite deposits of the membrane attack complex, the rapsyn-overexpressing muscles showed no decrement in the CMAPs, no loss of AChR, and the majority had normal postsynaptic folds, whereas endplates of untreated muscles showed typical AChR loss and morphological damage. These data suggest not only that increasing rapsyn expression could be a potential treatment for selected muscles of myasthenia gravis patients, but also lend support to the hypothesis that individual differences in innate rapsyn expression could be a factor in determining disease severity.
Collapse
MESH Headings
- Action Potentials/physiology
- Acute Disease
- Animals
- Electromyography/methods
- Female
- Fluorescent Antibody Technique/methods
- Immunohistochemistry/methods
- Microscopy, Confocal/methods
- Microscopy, Electron/methods
- Muscle Proteins/analysis
- Muscle Proteins/genetics
- Muscle, Skeletal/pathology
- Muscle, Skeletal/physiopathology
- Myasthenia Gravis, Autoimmune, Experimental/genetics
- Myasthenia Gravis, Autoimmune, Experimental/pathology
- Myasthenia Gravis, Autoimmune, Experimental/physiopathology
- Neuromuscular Junction/genetics
- Neuromuscular Junction/pathology
- Neuromuscular Junction/physiopathology
- Radioimmunoassay/methods
- Rats
- Rats, Inbred Lew
- Receptors, Cholinergic/genetics
- Synaptic Transmission/genetics
- Synaptic Transmission/physiology
- Up-Regulation/genetics
Collapse
Affiliation(s)
- Mario Losen
- Department of Neurology, Research Institute Brain and Behaviour, University of Maastricht, The Netherlands
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
De Baets M, Stassen M, Losen M, Zhang X, Machiels B. Immunoregulation in Experimental Autoimmune Myasthenia Gravis-about T Cells, Antibodies, and Endplates. Ann N Y Acad Sci 2003; 998:308-17. [PMID: 14592888 DOI: 10.1196/annals.1254.033] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Experimental autoimmune myasthenia gravis (EAMG) can be induced in a large number of animal species by active immunization (AI) AChR, by passive transfer (PT) of anti-AChR antibodies, by autologous bone marrow transplantation and cyclosporin (BMT-Cy), or spontaneously. Depending on the model used, different immunological mechanisms are operational. In the AI model, the T cell is pivotal in directing the anti-AChR antibody production towards pathogenic, that is, cross-linking and complement-fixing antibodies. Injection of anti-AChR antibodies alone suffices to induce EAMG, excluding the role of specific cell-mediated immune responses in the effector phase of the disease. Aged animals are resistant to the induction of AI and PT EAMG. This resistance is localized at the postsynaptic membrane containing more AChR-anchoring proteins, including S-laminin and rapsyn in aged animals. In BMT-CyA EAMG, a dysregulation of the immune system in the absence of immunization is capable of inducing myasthenia. The role of these animal models in relation to pathogenesis and immunotherapy is discussed.
Collapse
Affiliation(s)
- M De Baets
- Department of Neurology, Research Institute of Brain and Behavior, University of Maastricht, 6229 ER Maastricht, The Netherlands.
| | | | | | | | | |
Collapse
|
7
|
Abstract
Myasthenia gravis is an autoimmune disease associated with antibodies directed to the postsynaptic acetylcholine receptor. These antibodies reduce the number of receptors. Autoantibodies against AChR and other muscle antigens can be used for the diagnosis of myasthenia gravis and related disorders. The origin and the role of these antibodies in the disease are discussed. Experimental autoimmune myasthenia gravis, an experimental model closely mimicking the disease, has provided answers to many questions about the role of antibodies, complement macrophages and AChR anchor proteins. Genetically modified anti-AChR antibodies may also be used in the future to treat myasthenia.
Collapse
Affiliation(s)
- M De Baets
- Department of Neurology, University Hospital Maastricht, PO Box 5800, 6202 AZ Maastricht, The Netherlands.
| | | |
Collapse
|
8
|
Abstract
After an introduction on the development of biological ageing research in the Netherlands during the past decades, 606 papers on aging published by Dutch institutes in the period 1991-2000, collected from PubMed, were analysed for their relevance to research into biological ageing. For the period 1996-2000, the total number of research papers on biological ageing amounted to 142, which accounts for 23% of all publications on ageing in that period. The number of publications per year did not change. On the basis of these papers and additional information provided by research groups a comprehensive overview of biological ageing research in the Netherlands is presented, together with an extensive literature list. Ageing of the central nervous system (CNS), of the endocrinological system and of the cardiovascular system are the topics most studied. It is concluded that general biological ageing research has not increased in the Netherlands over the last ten years, and that the infrastructure for basic biological ageing research in the Netherlands is weak.
Collapse
Affiliation(s)
- P Huijbers
- Netherlands Institute for Care and Welfare, NIZW, P.O. Box 19152, 3500 DD Utrecht, The Netherlands.
| | | |
Collapse
|
9
|
Wang HB, Li H, He B, Bakheit M, Levi M, Wahren B, Berglöf A, Sandstedt K, Link H, Shi FD. The role of B-cells in experimental myasthenia gravis in mice. Biomed Pharmacother 1999; 53:227-33. [PMID: 10424244 DOI: 10.1016/s0753-3322(99)80093-6] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
Myasthenia gravis (MG) and experimental autoimmune myasthenia gravis (EAMG) are caused by auto-antibodies against the nicotinic acetylcholine receptor (AChR) at the postsynaptic membrane. To evaluate the extent to which the humoral immune response against AChR operates in the pathogenesis of EAMG, we immunized B-cell knockout (microMT) and wild type C57BL/6 mice with AChR in complete Freund's adjuvant. The ability of AChR-primed lymph node cells to proliferate and secrete IFN-gamma in response to AChR and its dominant peptide alpha 146-162 were intact in microMT as in wild type mice. Similar levels of mRNA for IFN-gamma, IL-4 and IL-10 in AChR-reactive lymph node cells were detected in microMT and wild type mice. However, microMT mice had no detectable anti-AChR antibodies and never developed clinical EAMG. We conclude that B-cells are critically required for the genesis of clinical EAMG, but not for AChR-specific T-cell priming.
Collapse
Affiliation(s)
- H B Wang
- Division of Neurology, Karolinska Institutet, Stockholm, Sweden
| | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Li H, Shi FD, Bai X, Huang Y, Diab A, He B, Link H. Cytokine and chemokine mRNA expressing cells in muscle tissues of experimental autoimmune myasthenia gravis. J Neurol Sci 1998; 161:40-6. [PMID: 9879680 DOI: 10.1016/s0022-510x(98)00181-6] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
In-situ hybridization with labeled oligonucleotide probes was applied to explore cytokine and chemokine mRNA expression in sections of striated muscle, the target organ in experimental autoimmune myasthenia gravis (EAMG), induced in Lewis rats by immunization with acetylcholine receptor (AChR) and complete Freund's adjuvant (CFA). A transient burst of TNF-alpha, IL-1beta and IL-6 mRNA expressing cells was detected during the early phase of EAMG. This cytokine pattern was related to muscular infiltration of macrophages. Levels of IL-4, IL-10, IFN-gamma, cytolysin and TGF-beta mRNA expressing cells were low and observed mainly during the early phase of EAMG. C-C chemokine RANTES, MCP, MIP-1alpha and MIP-2 mRNA expressing cells were not detected over the course of EAMG. The low and transient expression of cytokines in EAMG muscle tissues suggests that the immune effector responses are unlikely operated by infiltrating cells in muscle. Muscular infiltrations in EAMG are unlikely due to local accumulation of C-C chemokines.
Collapse
Affiliation(s)
- H Li
- Division of Neurology, Karolinska Institute, Huddinge University Hospital, Stockholm, Sweden
| | | | | | | | | | | | | |
Collapse
|
11
|
Hoedemaekers A, Bessereau JL, Graus Y, Guyon T, Changeux JP, Berrih-Aknin S, van Breda Vriesman P, De Baets MH. Role of the target organ in determining susceptibility to experimental autoimmune myasthenia gravis. J Neuroimmunol 1998; 89:131-41. [PMID: 9726835 DOI: 10.1016/s0165-5728(98)00126-x] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Injection of anti-AChR antibodies in passive transfer experimental autoimmune myasthenia gravis (EAMG) results in increased degradation of acetylcholine receptor (AChR) and increased synthesis of AChR alpha-subunit mRNA. Passive transfer of anti-Main Immunogenic Region (MIR) mAb 35 in aged rats does not induce clinical signs of disease nor AChR loss. The expression of the AChR subunit genes was analyzed in susceptible and resistant rats. In aged EAMG resistant rats, no increase in the amount of AChR alpha-subunit mRNA was measured. In vivo AChR degradation experiments did not show any increase in AChR degradation rates in aged resistant rats, in contrast to young susceptible rats. Taken together, these data demonstrate that resistance of the AChR protein to antibody-mediated degradation is the primary mechanism that accounts for the resistance to passive transfer EAMG in aged rats.
Collapse
MESH Headings
- Aging/immunology
- Animals
- Antibodies, Monoclonal/pharmacology
- Autoimmunity/immunology
- Biopsy
- Disease Models, Animal
- Female
- Gene Expression/immunology
- Muscle Denervation
- Muscle, Skeletal/immunology
- Muscle, Skeletal/innervation
- Muscle, Skeletal/pathology
- Myasthenia Gravis/immunology
- Neuromuscular Junction/chemistry
- Neuromuscular Junction/immunology
- Neuromuscular Junction/metabolism
- RNA, Messenger/analysis
- Rats
- Rats, Inbred BN
- Receptors, Cholinergic/genetics
- Receptors, Cholinergic/immunology
- Receptors, Cholinergic/metabolism
- Sciatic Nerve/surgery
- Synapses/chemistry
- Synapses/immunology
- Synapses/metabolism
- Up-Regulation/genetics
Collapse
Affiliation(s)
- A Hoedemaekers
- Maastricht University, Department of Immunology, The Netherlands
| | | | | | | | | | | | | | | |
Collapse
|
12
|
Abstract
Combining in situ tailing and immunocytochemical staining, we demonstrated that the infiltrating macrophages in muscle tissue sections during early phase of experimental autoimmune myasthenia gravis (EAMG) in Lewis rats were eliminated by apoptosis at high frequency. These apoptotic macrophages were colocalized in the end-plate regions. Apoptosis is a major cause for elimination of infiltrating macrophages during the early phase of EAMG.
Collapse
Affiliation(s)
- F D Shi
- Division of Neurology, Karolinska Institute, Huddinge University Hospital, Stockholm, Sweden.
| | | | | | | |
Collapse
|
13
|
Hoedemaekers A, Bessereau JL, Graus Y, Guyon T, Changeux JP, Berrih-Aknin S, Van Breda Vriesman P, De Baets M. Differential susceptibility of young and old rat neuromuscular junctions to antibody-mediated AChR degradation in experimental autoimmune myasthenia gravis. Ann N Y Acad Sci 1998; 841:550-4. [PMID: 9668293 DOI: 10.1111/j.1749-6632.1998.tb10981.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- A Hoedemaekers
- Department of Immunology, Maastricht University, The Netherlands
| | | | | | | | | | | | | | | |
Collapse
|
14
|
Hoedemaekers AC, van Breda Vriesman PJ, De Baets MH. Myasthenia gravis as a prototype autoimmune receptor disease. Immunol Res 1997; 16:341-54. [PMID: 9439759 DOI: 10.1007/bf02786398] [Citation(s) in RCA: 24] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Myasthenia gravis (MG) is an organ-specific autoimmune disease in which autoantibodies against nicotinic acetylcholine receptors (AChR) at the postsynaptic membrane cause loss of functional AChR and disturbed neuromuscular transmission. The immunopathogenic mechanisms responsible for loss of functional AChR include antigenic modulation by anti-AChR antibodies, complement-mediated focal lysis of the postsynaptic membrane, and direct interference with binding of acetylcholine to the AChR or with ion channel function. The loss of AChR and subsequent defective neuromuscular transmission is accompanied by increased expression of the different AChR subunit genes, suggesting a role for the target organ itself in determining susceptibility and severity of disease. Experimental autoimmune myasthenia gravis (EAMG) is an animal model for the disease MG, and is very suitable to study the immunopathogenic mechanisms leading to AChR loss and the response of the AChR to this attack. In this article the current concepts of the structure and function of the AChR and the immunopathological mechanisms in MG and EAMG are reviewed.
Collapse
Affiliation(s)
- A C Hoedemaekers
- Department of Immunology, Maastricht University, Maastricht, The Netherlands
| | | | | |
Collapse
|